KU-19-19 Xenograft Model Service for Bladder Cancer

The KU-19-19 Xenograft Model Service for Bladder Cancer provides a robust, clinically relevant platform for evaluating novel therapeutic strategies against muscle-invasive urothelial carcinoma. Alfa Cytology leverages this well-characterized cell line to deliver reproducible, high-quality preclinical xenograft studies tailored to your drug development pipeline, ensuring reliable pharmacological and efficacy data from early-stage candidate screening through to late-phase validation.

Overview of KU-19-19 Xenograft Model for Bladder Cancer

The KU-19-19 cell line was established in 1993 from a metastatic, grade 3 (WHO classification) invasive transitional cell carcinoma of the bladder, derived from a 76-year-old male patient presenting with stage pT3b disease. This line exhibits epithelial morphology with prominent microvilli and tight junctions ultrastructurally, and is notable for its constitutive secretion of multiple hematopoietic cytokines---including granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), stem cell factor (SCF), interleukin-1alpha (IL-1alpha), interleukin-6 (IL-6), interleukin-8 (IL-8), and beta-human chorionic gonadotropin (beta-hCG). These secretory properties, combined with its demonstrated xenograft transplantability in immunodeficient mice associated with severe host neutrophilia, render KU-19-19 a uniquely informative model for studying tumor-microenvironment interactions, paraneoplastic syndromes, and the biological behavior of advanced bladder carcinoma.

In preclinical oncology, KU-19-19 xenografts have been widely adopted as a muscle-invasive bladder cancer (MIBC) model for compound efficacy screening, combination therapy evaluation, and biomarker discovery. The cell line's hypertriploid karyotype (approximately 74 chromosomes) and documented molecular alterations provide a genomically relevant backdrop for testing targeted agents. Furthermore, KU-19-19 cells have been successfully engineered with reporter constructs (e.g., GFP/firefly luciferase) to enable non-invasive longitudinal monitoring of tumor growth and metastatic dissemination via in vivo imaging systems, expanding their utility in orthotopic implantation studies and advanced pharmacodynamic assessments.

Figure 1. Similar signatures, Signature PT-A and PT-B, were identified in KU 19--19 cells exposed to purified PT. (Wong, K, et al., 2023)

Cell Line Information: KU-19-19

KU-19-19 is a human bladder transitional cell carcinoma cell line with well-documented pathological, morphological, and molecular characteristics. The following table summarizes key attributes relevant to preclinical model development and experimental design:

Our Services

Alfa Cytology provides comprehensive KU-19-19 xenograft model services engineered to accelerate your preclinical bladder cancer drug development programs. Our integrated platform encompasses cell line authentication, orthotopic and subcutaneous implantation, longitudinal tumor monitoring via advanced imaging modalities, comprehensive pharmacokinetic and pharmacodynamic profiling, and detailed histopathological endpoint analysis. With stringent quality control measures, experienced study directors, and customizable dosing regimens, we ensure that every study generates actionable, publication-ready data to support your IND-enabling decisions and therapeutic candidate prioritization.

Workflow of KU-19-19 Xenograft Model Construction

Construction of the KU-19-19 xenograft model at Alfa Cytology follows a standardized, GLP-compliant workflow designed to ensure reproducibility, ethical compliance, and scientific rigor. The process integrates cell line quality verification, immunodeficient host selection, precise tumor cell inoculation, and systematic endpoint evaluation to deliver robust preclinical datasets.

1. Cell Line Expansion & Authentication: KU-19-19 cells are expanded from authenticated master stocks (DSMZ ACC 395) under standardized culture conditions (RPMI 1640 + 10% FBS, 37 degrees C, 5% CO2). Prior to implantation, cells undergo STR profiling verification, mycoplasma screening, and viability assessment to ensure genetic integrity and optimal tumorigenic potential.
2. Host Selection & Preparation: Immunodeficient mice (typically BALB/c nude or NSG strains, 6--8 weeks old) are acclimatized under pathogen-free conditions. For orthotopic models, surgical preparation and bladder wall exposure are performed under anesthesia; for subcutaneous models, the flank region is prepared aseptically.
3. Tumor Cell Inoculation: For subcutaneous xenografts, 5--10 x 10^6 KU-19-19 cells in 100--200 uL PBS/Matrigel (1:1) are injected into the flank. For orthotopic implantation, cells are instilled into the bladder lumen via transurethral catheterization or directly injected into the bladder wall, depending on study objectives.
4. Tumor Monitoring & Imaging: Tumor growth is monitored via caliper measurement (subcutaneous) or non-invasive bioluminescence/fluorescence imaging (orthotopic/reporter lines) twice weekly. Body weight, clinical signs, and tumor burden are recorded systematically to ensure humane endpoints and data integrity.
5. Treatment Administration: Upon reaching designated tumor volume (typically 100--200 mm^3 for subcutaneous models), animals are randomized into treatment cohorts. Test compounds are administered via predetermined routes (oral gavage, intraperitoneal, intravenous, or intravesical) according to client-specific protocols.
6. Endpoint Analysis & Data Reporting: Studies conclude with tumor excision, weight measurement, and comprehensive histopathological evaluation (H&E, IHC, IF). Additional analyses include cytokine profiling, pharmacokinetic sampling, biomarker quantification, and digital pathology reporting, delivered as a customized study report.

Figure 2. KU-19-19 xenograft model construction workflow.

Case Study-KU-19-19 Xenograft Model Development

Alfa Cytology has successfully established and validated the KU-19-19 xenograft model across multiple study configurations, including subcutaneous flank implantation in BALB/c nude mice and orthotopic bladder wall injection in NSG mice utilizing luciferase-transfected reporter cells. Across these platforms, we have consistently observed robust tumor take rates, predictable growth kinetics, and measurable responses to standard-of-care reference compounds, providing a reliable foundation for client-specific therapeutic evaluations. Detailed efficacy data, tumor growth curves, pharmacokinetic profiles, and histopathological findings are available upon request under confidentiality agreements---please contact our business development team to schedule a data review session tailored to your program requirements.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your KU-19-19 xenograft studies ensures access to a scientifically rigorous, operationally flexible, and compliance-driven preclinical service platform. Our dedicated oncology team combines deep disease-area expertise with streamlined project management to accelerate your timeline without compromising data quality.

• Authenticated cell banking with documented STR profiles and routine mycoplasma monitoring to ensure model fidelity.
• Flexible study designs encompassing subcutaneous, orthotopic, and metastatic model configurations with optional reporter imaging integration.
• GLP-compliant workflows, IACUC oversight, and AAALAC-accredited facilities guaranteeing ethical and regulatory standards.
• Comprehensive endpoint capabilities including digital histopathology, multiplex cytokine analysis, PK/PD correlation, and biomarker quantification.
• Dedicated project management with transparent milestone tracking, interim data reviews, and customized reporting formats to align with your internal decision-making processes.
• Competitive timelines and scalable capacity to accommodate everything from pilot proof-of-concept studies to large-scale combination therapy screens.

Contact Us

Ready to advance your bladder cancer therapeutic pipeline with the KU-19-19 xenograft model? Reach out to Alfa Cytology today to discuss your specific study requirements, review available validation data, and receive a customized proposal aligned with your preclinical objectives. Our scientific team is standing by to help you design the optimal study and deliver the high-quality data you need to move your candidates forward---contact us now to get started. Please reach out to us today via our inquiry form or email to learn more about our KU-19-19 Xenograft Model services.

For research use only. Not intended for any clinical use.